Author

D.-K. Ryu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Kim· 3 shared K.-S. Kwon· 3 shared S.-Y. Lee· 3 shared A. S. Tijsma· 2 shared B. Kang· 2 shared H. Noh· 2 shared H.-Y. Chung· 2 shared J.-I. Kim· 2 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

C. Kim

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The in vitro and in vivo potency of CT-P59 against Delta and its associated variants of SARS-CoV-2

D.-K. Ryu, H.-M. Woo, B. Kang, H. Noh, J.-I. Kim, J.-M. Seo, C. Kim, M. Kim, J.-W. Kim, N. Kim, P. Jeon, H. Lee, J.-S. Yang, K.-C. Kim, J.-Y. Lee, , S.-Y. Lee

This study evaluates CT-P59's antiviral activity against Delta and its variants, showing reduced in vitro potency but effective in vivo neutralization and symptom remission in mice.

bioRxiv · Jul 23, 2021 · PreprintMicrobiology

Therapeutic efficacy of CT-P59 against P.1 variant of SARS-CoV-2

S.-Y. Lee, D.-K. Ryu, b. Kang, H. Noh, J. Kim, J.-M. Seo, C. Kim, C. v. Baalen, A. S. Tijsma, H.-Y. Chung, M.-H. Lee, S.-S. Oh, J.-a. Choi, M. Song, K.-S. Kwon

This study evaluates CT-P59's efficacy against the P.1 SARS-CoV-2 variant through in vitro and in vivo tests, showing reduced in vitro neutralization but therapeutic benefit in mice.

bioRxiv · Jul 8, 2021 · PreprintMicrobiology

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant

S.-Y. Lee, D.-K. Ryu, Y. K. Choi, P. Moore, C. A. v. Baalen, r. song, A. S. Tijsma, T. Gwete-Moyo, M. Kim, Y.-I. Kim, C. Kim, J.-I. Kim, K.-S. Kwon

This study evaluates CT-P59's efficacy against SARS-CoV-2 variants, showing reduced in vitro neutralization but effective in vivo therapeutic potential against the B.1.351 variant.

bioRxiv · Apr 27, 2021Microbiology